SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.
Study shows adding tiragolumab to immunotherapy didn't improve survival in lung cancer, redirecting research efforts.
SKYSCRAPER-03 did not meet its primary endpoint: tiragolumab plus atezolizumab showed no improvement in PFS over durvalumab in PD-L1+ or all-comers stage III NSCLC (HR 0.96; 95% CI 0.75–1.23). This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- phase_3_rct
- Category
- Other
- Maturity
- Validated
- Journal
- Ann Oncol
Why it surfaced
High-impact negative Phase 3 RCT for TIGIT+PD-L1 blockade in stage III NSCLC; published in Annals of Oncology with full data including OS; shapes the development strategy for anti-TIGIT agents across immuno-oncology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.